RMD 1203
Alternative Names: RMD-1203Latest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Remedium Bio
- Class Antihyperglycaemics; Gene therapies; Obesity therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 06 Nov 2024 Preclinical trials in Obesity in USA (SC) before November 2024 (Remedium Bio pipeline, November 2024)
- 06 Nov 2024 Preclinical trials in Type 2 diabetes mellitus in USA (SC) before November 2024 (Remedium Bio pipeline, November 2024)